Abstract
Chronic lymphocytic leukemia (CLL) is a common adult leukemia in the Western world with an incidence of 4.2/100,000/year. The clinical course of disease is highly heterogenous; it affects people over 65-70 years of age. This hematologic cancer is characterized by the resistance to apoptosis stimuli predominantly associated with overexpression of antiapoptotic Bcl-2 family members. Therapeutic options for advanced CLL patients are limited. Thus there is an urgent need to discover a novel, less toxic, and much more effective agent(s) or drug combinations for CLL patients. Among chemotherapeutic(s) and immunotherapeutics currently in use, several enzyme inhibitors were tested to gain better results in CLL treatment. Here, we review the main achievements made on targeting of prosurvival Bcl-2 proteins through the use of different approaches, i.e. anti-sense methodology, small molecules that mimic the action of BH3 domain and microRNAs (mainly miRNA-15a and miRNA-16-1).
Keywords: Antileukemic therapy, antisense oligonucleotides, small molecular Bcl-2 inhibitors, BH3 domain mimetics, CLL, microRNA-15a/16-1, oblimersen, obatoclax, gossypol derivatives, ABT-737, ABT-263
Current Medicinal Chemistry
Title:Targeting Bcl-2 in CLL
Volume: 19 Issue: 30
Author(s): M. Rogalinska and Z.M. Kilianska
Affiliation:
Keywords: Antileukemic therapy, antisense oligonucleotides, small molecular Bcl-2 inhibitors, BH3 domain mimetics, CLL, microRNA-15a/16-1, oblimersen, obatoclax, gossypol derivatives, ABT-737, ABT-263
Abstract: Chronic lymphocytic leukemia (CLL) is a common adult leukemia in the Western world with an incidence of 4.2/100,000/year. The clinical course of disease is highly heterogenous; it affects people over 65-70 years of age. This hematologic cancer is characterized by the resistance to apoptosis stimuli predominantly associated with overexpression of antiapoptotic Bcl-2 family members. Therapeutic options for advanced CLL patients are limited. Thus there is an urgent need to discover a novel, less toxic, and much more effective agent(s) or drug combinations for CLL patients. Among chemotherapeutic(s) and immunotherapeutics currently in use, several enzyme inhibitors were tested to gain better results in CLL treatment. Here, we review the main achievements made on targeting of prosurvival Bcl-2 proteins through the use of different approaches, i.e. anti-sense methodology, small molecules that mimic the action of BH3 domain and microRNAs (mainly miRNA-15a and miRNA-16-1).
Export Options
About this article
Cite this article as:
Rogalinska M. and Kilianska Z.M., Targeting Bcl-2 in CLL, Current Medicinal Chemistry 2012; 19 (30) . https://dx.doi.org/10.2174/092986712803530566
DOI https://dx.doi.org/10.2174/092986712803530566 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Modeling Applied to Anti-Cancer Drug Development
Anti-Cancer Agents in Medicinal Chemistry Pharmacokinetic Properties of Rituximab
Reviews on Recent Clinical Trials Role of microRNAs in Chronic Lymphocytic Leukemia Pathogenesis
Current Medicinal Chemistry The Impact of CRISPR/Cas9-Based Genomic Engineering on Biomedical Research and Medicine
Current Molecular Medicine Chemotherapeutic Effects of Acridine Derivatives
Medicinal Chemistry Reviews - Online (Discontinued) Neuro-Inflammatory Mechanisms in Developmental Disorders Associated with Intellectual Disability and Autism Spectrum Disorder: A Neuro- Immune Perspective
CNS & Neurological Disorders - Drug Targets Distribution, Bioactivities and Therapeutical Potentials of Pentagalloylglucopyranose
Current Bioactive Compounds Cancer-Specific Ligands Identified from Screening of Peptide-Display Libraries
Current Pharmaceutical Design Therapeutic Potential of microRNA Against Th2-associated Immune Disorders
Current Topics in Medicinal Chemistry Coordinated Expression of Pax-5 and FAK1 in Metastasis
Anti-Cancer Agents in Medicinal Chemistry Versatile and Valuable Utilization of Amidohydrolase L-glutaminase in Pharma and Food industries: A Review
Current Drug Metabolism Innovative Cell Therapy in the Treatment of Serious Adverse Events Related to Both Chemo-Radiotherapy Protocol and Acute Myeloid Leukemia Syndrome: The Infusion of Mesenchymal Stem Cells Post-Treatment Reduces Hematopoietic Toxicity and Promotes Hematopoietic Reconstitution
Current Pharmaceutical Biotechnology Immunological Aspects of Adult T-Cell Leukemia/Lymphoma (ATLL), a Possible Neoplasm of Regulatory T-Cells
Current Immunology Reviews (Discontinued) Pharmacological Properties and Therapeutic Possibilities for Drugs Acting Upon Endocannabinoid Receptors
Current Drug Targets - CNS & Neurological Disorders Curcumin: the Yellow Molecule with Pleiotropic Biological Effects
Letters in Drug Design & Discovery Regulatory Overview of Biosimilars: Current Scenario and Future Opportunities
Applied Clinical Research, Clinical Trials and Regulatory Affairs Environmental Factors Contributing to Susceptibility to Tuberculosis
Current Respiratory Medicine Reviews Bioenergetics Pathways and Therapeutic Resistance in Gliomas: Emerging Role of Mitochondria
Current Pharmaceutical Design Ribozyme- and Deoxyribozyme-Strategies for Medical Applications
Current Drug Targets Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma
Current Cancer Drug Targets